About ▼ Careers Internship MedBlog Contact us

LOGIN REGISTER

Advertisement

Medindia » Health Press Releases A-Z

BioPharmX Data Suggest Anti-Inflammatory Activity of BPX-01 Topical Minocycline Gel

Advertisement

Poster presentation at ODAC Conference reports potential anti-inflammatory properties of minocycline

Advertisement

BioPharmX (BPMX) (PRNewsFoto/BioPharmX Corporation)

Sponsored Post and Backlink Submission

Latest Press Release on Drug News

UT Health San Antonio to lead $11 million, NIH-funded study of a first-ever oral chlamydia vaccine

The University of Texas Health Science Center at San Antonio (UT Health San Antonio) will direct a team of researchers to investigate a novel oral vaccine for chlamydia, the most rep...

GIBF invests $10 Million in Nectin Therapeutics to Advance Novel Pipeline of First-in-Class Immunotherapies and Antibody Drug Conjugates

Proceeds from financing to support ongoing clinical development of lead program targeting PVR as well as IND-enabling activities for multiple ADC candidates TEL AVIV, Israel , ...

Recently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three Seasons

A real-world evidence (RWE) study recently published in Open Forum Infectious Diseases (OFID) examined three consecutive U.S. flu seasons in the United States . The study suggests th...

Foresee Pharmaceuticals Announces First Subject Dosed in its First-in-Human Clinical Trial of FP-020

TAIPEI , April 30, 2024 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced that the first subject has been dosed in its Phase 1 clinical trial of FP...

PANTHERx® Rare Partnering with X4 Pharmaceuticals Inc. for the Distribution of XOLREMDI™ (mavorixafor), the First FDA-Approved Therapy Indicated for Use in Patients with WHIM Syndrome

PITTSBURGH , April 29, 2024 /PRNewswire/ -- PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, today announced it was selec...

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use Ok, Got it. Close